A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

3,539

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

August 31, 2007

Study Completion Date

January 31, 2008

Conditions
Meningococcal InfectionsMeningococcal Meningitis
Interventions
BIOLOGICAL

MenACWY CRM

One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.

BIOLOGICAL

Meningococcal ACWY Conjugate vaccine

One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly.

Trial Locations (40)

15025

Jefferson Borough

15090

Wexford

15106

Carnegie

15241

Upper Saint Clair

15301

Washington

15401

Uniontown

15650

Latrobe

16125

Greenville

16127

Grove City

16505

Erie

18960

Sellersville

19438

Harleyville

21201

Baltimore

21401

Annapolis

21702

Frederick

30062

Atlanta

Marietta

30189

Woodstock

35487

Tuscaloosa

40004

Bardstown

44121

South Euclid

44308

Akron

45229

Cincinnati

60614

Chicago

80218

Denver

84121

Salt Lake City

93726

Fresno

94538

Fremont

94545

Hayward

94612

Oakland

95119

San Jose

95661

Roseville

95817

Sacramento

35205, 35244

Birmingham

02118

Boston

02124

Fall River

03756

Lebanon

15217 to 15241

Pittsburgh

77555-0371

Galveston

98101-1466

Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novartis Vaccines

INDUSTRY